Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals is on the brink of a breakthrough with its latest submission of label materials for Sofdra, its innovative treatment for excessive underarm sweating, to the FDA. With the labeling discussions concluding, the company is poised for the expected FDA approval on June 21, 2024. Sofdra stands out as it could become the first new chemical entity approved for primary axillary hyperhidrosis, marking a significant milestone for Botanix and offering new hope for patients.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
